Modular Pharma Factories: The Next Step for Continuous Manufacturing?

Modular pharmaceutical manufacturing is emerging as a practical solution to one of the industry's biggest operational challenges: Building production facilities that can adapt as quickly as modern medicines evolve.

As demand grows for personalised medicines, biologics, and shorter product lifecycles, traditional manufacturing plants are increasingly struggling to provide the flexibility needed to remain competitive.

Image

Why Pharmaceutical Manufacturing Needs Greater Flexibility

Pharmaceutical manufacturing has traditionally prioritised stability, consistency, and long-term production.

Facilities are often designed around a single manufacturing process, requiring substantial investment and years of planning before production begins.

While this approach has served blockbuster medicines well, today's pharmaceutical landscape looks very different.

Companies are increasingly manufacturing:

• smaller commercial batches
• precision medicines
• cell and gene therapies
• orphan drugs
• highly potent compounds
• rapidly evolving biologics

Many products now have shorter commercial lifecycles and greater manufacturing complexity than conventional small molecules.

At the same time, global supply chains have become more volatile. The COVID-19 pandemic, geopolitical uncertainty, and increasing regional manufacturing initiatives have highlighted the importance of production resilience alongside efficiency.

These trends are encouraging manufacturers to move away from static facilities towards modular production systems that can evolve over time.

A recent article published in the International Journal of Production Research argues that reconfigurable modular factories, combined with continuous pharmaceutical manufacturing, could fundamentally reshape how medicines are produced.

Rather than relying on large, fixed facilities designed for decades of operation, manufacturers could deploy adaptable production systems capable of changing alongside new products, technologies, and market demand.

What Is a Modular, Reconfigurable Pharmaceutical Factory?

Modular factories are manufacturing environments built from independent production units that can be added, removed, relocated, or reconfigured without redesigning the entire facility.

Instead of constructing one large manufacturing line, companies develop smaller process modules that perform specific operations.

These may include:

• raw material handling
• feeding systems
• continuous blending
• granulation
• drying
• tableting
• coating
• packaging
• in-line quality monitoring

Each module operates as part of an integrated production platform but can be upgraded or replaced independently as manufacturing requirements change.

This creates a production environment that is considerably more adaptable than conventional facilities, making reconfigurability is becoming just as important as manufacturing efficiency.

Continuous Manufacturing Enables Modular Production

Continuous manufacturing is the technology that makes modular factories commercially viable.

Unlike traditional batch manufacturing, continuous production allows materials to move through connected processing steps without interruption.

Instead of stopping between manufacturing stages, production becomes an integrated flow.

Image

This offers several operational advantages:

Greater production flexibility

Manufacturing capacity can be increased by adding modules rather than constructing entirely new production lines.

Faster product changeovers

Individual modules can be reconfigured to support different medicines with reduced downtime.

Improved quality assurance

Continuous monitoring enables manufacturers to detect process variation immediately rather than waiting until batch completion.

Better resource efficiency

Continuous systems typically reduce material waste, lower energy consumption, and improve equipment utilisation.

These benefits become increasingly valuable as pharmaceutical portfolios become more diverse and production volumes less predictable.

Digital Technologies Are the Manufacturing Control System

Modular factories depend on more than physical equipment.

Digital technologies increasingly provide the intelligence required to coordinate flexible manufacturing environments.

Such technologies include:

Process Analytical Technology (PAT)

Real-time analytical tools continuously monitor critical process parameters throughout production.

Rather than relying solely on end-product testing, manufacturers gain immediate visibility into process performance.

Digital twins

Virtual representations of manufacturing systems allow companies to simulate process changes before implementing them on the production line.

This reduces operational risk while supporting faster optimisation.

Artificial intelligence

Machine learning algorithms can identify process trends, predict equipment performance, optimise production settings, and support predictive maintenance.

As modular facilities become more complex, AI is expected to play an increasingly important role in coordinating production across multiple manufacturing modules.

Together, these technologies create intelligent manufacturing systems capable of adapting to changing production requirements with minimal disruption.

Read Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

Beyond Operational Efficiency

Modular manufacturing is not simply an engineering innovation and it represents a strategic manufacturing model.

Traditional pharmaceutical facilities often require significant capital investment years before products generate commercial revenue.

Modular facilities offer a different approach.

By expanding capacity incrementally, manufacturers can better align investment with product demand.

Potential strategic advantages include:

• lower initial capital expenditure
• faster facility deployment
• improved manufacturing resilience
• easier technology upgrades
• greater regional manufacturing capability
• more efficient technology transfer between sites

For companies producing advanced therapies or medicines with uncertain demand, this flexibility could significantly reduce financial risk.

Read First Quarter 2026 State of Digital Health Funding

First Quarter 2026 State of Digital Health Funding

Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.

Image

Challenges Remain Before Widespread Adoption

The review also recognises that modular manufacturing is not yet a universal solution.

Several barriers remain:

Regulatory validation

Each manufacturing configuration must continue to demonstrate consistent product quality, regardless of how production modules are arranged.

This requires robust validation strategies and close collaboration with regulators.

Integration complexity

Although modular systems increase flexibility, integrating multiple equipment vendors, automation platforms, and digital control systems presents technical challenges.

Achieving seamless interoperability remains a priority for the industry.

Workforce transformation

Future manufacturing facilities will require multidisciplinary teams combining pharmaceutical science, automation engineering, data analytics, digital manufacturing, and quality management expertise.

Building these capabilities will be as important as investing in new production technologies.

Flexible Manufacturing as a Competitive Advantage

The pharmaceutical industry is entering an era where manufacturing agility is becoming as important as manufacturing capacity.

As medicine portfolios diversify and commercial uncertainty increases, facilities designed for maximum flexibility may prove more valuable than those designed solely for maximum output.

Modular, reconfigurable factories supported by continuous manufacturing and digital technologies could provide manufacturers with the adaptability needed to respond more quickly to changing products, evolving regulations, and future market demands.

The transition will not happen overnight. Regulatory harmonisation, technology integration, and workforce development remain important challenges. 

Modular manufacturing represents a strategic opportunity to build production networks that are more resilient, scalable, and capable of supporting the next generation of medicines.

At Pharmatica, we examine the technologies, operational strategies, and manufacturing innovations shaping the future of pharmaceutical production. By translating emerging research into practical industry Insights, we help life sciences leaders understand where technical innovation can deliver lasting competitive advantage across the pharmaceutical value chain.

Pharmatica: Insight. Connection. Impact.